Literature DB >> 18056457

An oncolytic adenovirus redirected with a tumor-specific T-cell receptor.

Zsolt Sebestyen1, Jeroen de Vrij, Maria Magnusson, Reno Debets, Ralph Willemsen.   

Abstract

To improve safety and specificity of oncolytic adenoviruses, we introduced T-cell receptors (TCR) specific for a unique class of truly tumor-specific antigens into the adenoviral fiber protein. The adenoviral fiber knob responsible for attachment to the coxsackie-adenoviral receptor (CAR) on target cells was replaced by a single-chain TCR (scTCR) molecule with specificity for the melanoma-associated cancer-testis antigen MAGE-A1, presented by HLA-A1, and an extrinsic trimerization motif in a replicating Ad5 vector (Ad5.R1-scTCR). The production of the recombinant virus was initiated in a novel producer cell line that expressed an antibody-based hexon-specific receptor (293T-AdR) in the cell membrane. This new production system allowed CAR-independent and target antigen-independent propagation of Ad5.R1-scTCR. Infection with adenovirus bearing the scTCR-based fiber resulted in an efficient killing of target tumor cells. The infection was cell type specific because only HLA-A1(+)/MAGE-A1(+) melanoma cells were killed, and thus, this retargeting strategy provides a versatile tool for future clinical application.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056457     DOI: 10.1158/0008-5472.CAN-07-0739

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.

Authors:  Zineb Belcaid; Martine L M Lamfers; Victor W van Beusechem; Rob C Hoeben
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

2.  Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.

Authors:  T J Harvey; D Burdon; L Steele; N Ingram; G D Hall; P J Selby; R G Vile; P A Cooper; S D Shnyder; J D Chester
Journal:  Gene Ther       Date:  2010-04-22       Impact factor: 5.250

3.  Development of a targeted gene vector platform based on simian adenovirus serotype 24.

Authors:  Natalya Belousova; Galina Mikheeva; Chiyi Xiong; Suren Soghomonian; Daniel Young; Lucia Le Roux; Katherine Naff; Luc Bidaut; Wei Wei; Chun Li; Juri Gelovani; Victor Krasnykh
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

4.  Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.

Authors:  Elena A Kashentseva; Joanne T Douglas; Kurt R Zinn; David T Curiel; Igor P Dmitriev
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

5.  Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats.

Authors:  A M Sonabend; I V Ulasov; Y Han; C E Rolle; S Nandi; D Cao; M A Tyler; M S Lesniak
Journal:  Cancer Gene Ther       Date:  2008-11-14       Impact factor: 5.987

6.  Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.

Authors:  Elisa Callegari; Bahaeldin K Elamin; Lucilla D'Abundo; Simonetta Falzoni; Giovanna Donvito; Farzaneh Moshiri; Maddalena Milazzo; Giuseppe Altavilla; Luciano Giacomelli; Francesca Fornari; Akseli Hemminki; Francesco Di Virgilio; Laura Gramantieri; Massimo Negrini; Silvia Sabbioni
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

7.  Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins.

Authors:  Elin Lunde; Geir Åge Løset; Bjarne Bogen; Inger Sandlie
Journal:  BMC Biotechnol       Date:  2010-08-24       Impact factor: 2.563

8.  The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

Authors:  Anne Kleijn; Jenneke Kloezeman; Elike Treffers-Westerlaken; Giulia Fulci; Sieger Leenstra; Clemens Dirven; Reno Debets; Martine Lamfers
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

Review 9.  Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Authors:  Hanni Uusi-Kerttula; Sarah Hulin-Curtis; James Davies; Alan L Parker
Journal:  Viruses       Date:  2015-11-24       Impact factor: 5.048

Review 10.  Designer Oncolytic Adenovirus: Coming of Age.

Authors:  Alexander T Baker; Carmen Aguirre-Hernández; Gunnel Halldén; Alan L Parker
Journal:  Cancers (Basel)       Date:  2018-06-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.